| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| T-Lymphocytes | 27 | 2024 | 1691 | 4.000 |
Why?
|
| Immunotherapy, Adoptive | 24 | 2024 | 821 | 3.680 |
Why?
|
| Receptors, Antigen, T-Cell | 15 | 2023 | 477 | 3.480 |
Why?
|
| Antigens, CD19 | 14 | 2024 | 177 | 2.950 |
Why?
|
| Lymphoma | 10 | 2024 | 324 | 2.890 |
Why?
|
| Hodgkin Disease | 6 | 2023 | 293 | 2.450 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 14 | 2024 | 1200 | 1.690 |
Why?
|
| Lymphoma, Non-Hodgkin | 5 | 2018 | 162 | 1.630 |
Why?
|
| Ki-1 Antigen | 3 | 2023 | 27 | 1.490 |
Why?
|
| Immunotherapy | 7 | 2023 | 662 | 1.390 |
Why?
|
| Cell- and Tissue-Based Therapy | 5 | 2023 | 157 | 1.140 |
Why?
|
| Lymphoma, T-Cell | 2 | 2024 | 64 | 1.050 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 3 | 2016 | 182 | 0.970 |
Why?
|
| Spectrum Analysis, Raman | 1 | 2024 | 24 | 0.900 |
Why?
|
| Hematologic Neoplasms | 4 | 2022 | 286 | 0.860 |
Why?
|
| T-Lymphocytes, Cytotoxic | 5 | 2019 | 501 | 0.750 |
Why?
|
| Drug Approval | 1 | 2021 | 40 | 0.720 |
Why?
|
| Neoplasm Recurrence, Local | 5 | 2024 | 1118 | 0.700 |
Why?
|
| Vidarabine | 3 | 2020 | 79 | 0.690 |
Why?
|
| Cyclophosphamide | 4 | 2020 | 422 | 0.610 |
Why?
|
| Neoplasms | 6 | 2024 | 2757 | 0.600 |
Why?
|
| Lymphoma, Large-Cell, Anaplastic | 1 | 2017 | 46 | 0.560 |
Why?
|
| Central Nervous System Neoplasms | 1 | 2019 | 194 | 0.550 |
Why?
|
| Immunoglobulin kappa-Chains | 1 | 2016 | 31 | 0.530 |
Why?
|
| Genetic Therapy | 5 | 2022 | 678 | 0.520 |
Why?
|
| Transplantation Conditioning | 3 | 2022 | 323 | 0.510 |
Why?
|
| Indoleamine-Pyrrole 2,3,-Dioxygenase | 1 | 2015 | 13 | 0.490 |
Why?
|
| Humans | 62 | 2024 | 123046 | 0.480 |
Why?
|
| Hematopoietic Stem Cells | 7 | 2006 | 534 | 0.470 |
Why?
|
| Caspase 9 | 2 | 2014 | 75 | 0.450 |
Why?
|
| Receptors, Antigen, B-Cell | 1 | 2014 | 29 | 0.450 |
Why?
|
| Antineoplastic Agents | 6 | 2018 | 1661 | 0.440 |
Why?
|
| Gene Expression Profiling | 4 | 2019 | 1679 | 0.440 |
Why?
|
| Antigens, CD | 1 | 2015 | 421 | 0.430 |
Why?
|
| Transplantation, Homologous | 9 | 2024 | 659 | 0.430 |
Why?
|
| Papillomavirus E7 Proteins | 1 | 2013 | 19 | 0.420 |
Why?
|
| Multiple Myeloma | 3 | 2021 | 169 | 0.410 |
Why?
|
| Oncogene Proteins, Viral | 1 | 2013 | 56 | 0.410 |
Why?
|
| Human papillomavirus 16 | 1 | 2013 | 47 | 0.410 |
Why?
|
| Antigens, Neoplasm | 5 | 2022 | 387 | 0.410 |
Why?
|
| Antilymphocyte Serum | 1 | 2012 | 56 | 0.400 |
Why?
|
| Retroviridae | 4 | 2022 | 194 | 0.390 |
Why?
|
| Anemia, Aplastic | 1 | 2012 | 58 | 0.390 |
Why?
|
| Epitopes | 3 | 2020 | 429 | 0.370 |
Why?
|
| Mesenchymal Stem Cell Transplantation | 2 | 2014 | 80 | 0.360 |
Why?
|
| Graft vs Host Disease | 4 | 2024 | 543 | 0.350 |
Why?
|
| Interleukin-15 | 2 | 2024 | 91 | 0.330 |
Why?
|
| Middle Aged | 20 | 2024 | 25972 | 0.330 |
Why?
|
| Bone Marrow Transplantation | 1 | 2012 | 578 | 0.330 |
Why?
|
| Salvage Therapy | 2 | 2021 | 193 | 0.330 |
Why?
|
| Antibodies, Monoclonal | 2 | 2015 | 1008 | 0.330 |
Why?
|
| Transplantation, Autologous | 4 | 2022 | 297 | 0.320 |
Why?
|
| Immunophenotyping | 4 | 2019 | 328 | 0.320 |
Why?
|
| Lymphocyte Activation | 6 | 2019 | 684 | 0.320 |
Why?
|
| Recombinant Fusion Proteins | 4 | 2018 | 764 | 0.320 |
Why?
|
| Herpesvirus 4, Human | 8 | 2023 | 663 | 0.320 |
Why?
|
| Antiviral Agents | 4 | 2024 | 743 | 0.310 |
Why?
|
| Adult | 20 | 2024 | 28972 | 0.310 |
Why?
|
| Hepatitis B | 1 | 2010 | 159 | 0.300 |
Why?
|
| Aged | 15 | 2024 | 19083 | 0.300 |
Why?
|
| Virus Diseases | 2 | 2023 | 279 | 0.300 |
Why?
|
| Repressor Proteins | 1 | 2013 | 816 | 0.290 |
Why?
|
| Combined Modality Therapy | 3 | 2021 | 1236 | 0.290 |
Why?
|
| Lymphocyte Depletion | 3 | 2024 | 124 | 0.290 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 3 | 2022 | 805 | 0.290 |
Why?
|
| Hepacivirus | 1 | 2009 | 241 | 0.280 |
Why?
|
| Treatment Outcome | 12 | 2018 | 12109 | 0.270 |
Why?
|
| CD28 Antigens | 3 | 2019 | 78 | 0.270 |
Why?
|
| Leukemia | 2 | 2024 | 375 | 0.270 |
Why?
|
| Young Adult | 10 | 2024 | 8832 | 0.270 |
Why?
|
| Male | 24 | 2024 | 60089 | 0.240 |
Why?
|
| Mice, SCID | 4 | 2015 | 570 | 0.240 |
Why?
|
| Clinical Trials as Topic | 3 | 2021 | 1080 | 0.240 |
Why?
|
| Female | 24 | 2024 | 65482 | 0.240 |
Why?
|
| Bone Marrow | 3 | 2021 | 324 | 0.240 |
Why?
|
| Tumor Escape | 2 | 2018 | 61 | 0.230 |
Why?
|
| Lymphoma, B-Cell | 2 | 2019 | 137 | 0.230 |
Why?
|
| Glypicans | 1 | 2024 | 39 | 0.230 |
Why?
|
| Animals | 21 | 2020 | 33796 | 0.230 |
Why?
|
| Alemtuzumab | 1 | 2024 | 88 | 0.230 |
Why?
|
| Leukemia, Myeloid, Acute | 2 | 2021 | 533 | 0.230 |
Why?
|
| Immunologic Memory | 3 | 2019 | 184 | 0.230 |
Why?
|
| Quinazolines | 1 | 2024 | 176 | 0.220 |
Why?
|
| Cell Separation | 2 | 2004 | 231 | 0.210 |
Why?
|
| Polymerase Chain Reaction | 3 | 2006 | 1584 | 0.210 |
Why?
|
| Cell Proliferation | 9 | 2024 | 2307 | 0.210 |
Why?
|
| Polymorphism, Restriction Fragment Length | 1 | 2003 | 143 | 0.210 |
Why?
|
| Sequence Analysis, Protein | 1 | 2003 | 49 | 0.210 |
Why?
|
| Cell Line, Tumor | 4 | 2020 | 3293 | 0.210 |
Why?
|
| Leukocyte Common Antigens | 1 | 2003 | 90 | 0.210 |
Why?
|
| Genes, Transgenic, Suicide | 2 | 2014 | 49 | 0.200 |
Why?
|
| Mice | 16 | 2020 | 17540 | 0.200 |
Why?
|
| Molecular Chaperones | 1 | 2003 | 167 | 0.200 |
Why?
|
| Cytomegalovirus Infections | 1 | 2024 | 217 | 0.200 |
Why?
|
| Heat-Shock Proteins | 1 | 2003 | 194 | 0.200 |
Why?
|
| Genetic Engineering | 2 | 2020 | 161 | 0.200 |
Why?
|
| Stem Cells | 2 | 2006 | 701 | 0.190 |
Why?
|
| Gene Transfer Techniques | 2 | 2015 | 357 | 0.190 |
Why?
|
| Graft vs Leukemia Effect | 1 | 2021 | 30 | 0.180 |
Why?
|
| Gene Frequency | 1 | 2003 | 715 | 0.180 |
Why?
|
| Lymphocyte Transfusion | 1 | 2021 | 57 | 0.180 |
Why?
|
| Virus Activation | 2 | 2012 | 86 | 0.180 |
Why?
|
| Basigin | 1 | 2020 | 14 | 0.180 |
Why?
|
| B-Lymphocytes | 2 | 2014 | 518 | 0.180 |
Why?
|
| Respiratory Syncytial Virus, Human | 1 | 2023 | 204 | 0.180 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 4 | 2022 | 1232 | 0.180 |
Why?
|
| Bendamustine Hydrochloride | 1 | 2020 | 14 | 0.180 |
Why?
|
| Neovascularization, Physiologic | 3 | 2006 | 211 | 0.180 |
Why?
|
| Cells, Cultured | 7 | 2018 | 3040 | 0.180 |
Why?
|
| United States Food and Drug Administration | 1 | 2021 | 148 | 0.170 |
Why?
|
| Myelodysplastic Syndromes | 1 | 2021 | 137 | 0.170 |
Why?
|
| Xenograft Model Antitumor Assays | 3 | 2020 | 887 | 0.170 |
Why?
|
| Recurrence | 5 | 2021 | 1418 | 0.170 |
Why?
|
| Cell Differentiation | 5 | 2019 | 1909 | 0.170 |
Why?
|
| SOXC Transcription Factors | 1 | 2019 | 8 | 0.170 |
Why?
|
| Genetic Variation | 1 | 2006 | 1479 | 0.170 |
Why?
|
| Respiratory Syncytial Virus Infections | 1 | 2023 | 334 | 0.170 |
Why?
|
| Bone Marrow Cells | 1 | 2021 | 260 | 0.170 |
Why?
|
| Virus Replication | 1 | 2022 | 603 | 0.160 |
Why?
|
| T-Lymphocyte Subsets | 1 | 2020 | 195 | 0.160 |
Why?
|
| Cytomegalovirus | 5 | 2024 | 269 | 0.160 |
Why?
|
| Stem Cell Transplantation | 1 | 2020 | 238 | 0.150 |
Why?
|
| Mitochondria | 1 | 2003 | 677 | 0.150 |
Why?
|
| Blood Platelets | 2 | 2019 | 333 | 0.150 |
Why?
|
| Remission Induction | 2 | 2016 | 300 | 0.150 |
Why?
|
| Positron Emission Tomography Computed Tomography | 1 | 2018 | 78 | 0.150 |
Why?
|
| Adoptive Transfer | 2 | 2016 | 237 | 0.150 |
Why?
|
| Cell Engineering | 1 | 2017 | 21 | 0.150 |
Why?
|
| Viral Matrix Proteins | 2 | 2018 | 109 | 0.140 |
Why?
|
| DNA Virus Infections | 1 | 2017 | 22 | 0.140 |
Why?
|
| Gene Expression Regulation | 3 | 2017 | 2524 | 0.140 |
Why?
|
| Adolescent | 9 | 2024 | 19075 | 0.140 |
Why?
|
| DNA Viruses | 1 | 2017 | 33 | 0.140 |
Why?
|
| Genetic Vectors | 5 | 2022 | 940 | 0.140 |
Why?
|
| Immunoconjugates | 1 | 2017 | 36 | 0.140 |
Why?
|
| Flow Cytometry | 3 | 2015 | 803 | 0.140 |
Why?
|
| Glenoid Cavity | 1 | 2016 | 3 | 0.140 |
Why?
|
| Herpesvirus 6, Human | 2 | 2017 | 58 | 0.130 |
Why?
|
| Cloning, Molecular | 3 | 2014 | 892 | 0.130 |
Why?
|
| Shoulder Joint | 1 | 2016 | 26 | 0.130 |
Why?
|
| Cytokines | 3 | 2024 | 1284 | 0.130 |
Why?
|
| Joint Instability | 1 | 2016 | 42 | 0.130 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2017 | 1681 | 0.130 |
Why?
|
| Wounds and Injuries | 1 | 2019 | 364 | 0.130 |
Why?
|
| Granulocyte Colony-Stimulating Factor | 2 | 2013 | 96 | 0.130 |
Why?
|
| Wound Healing | 1 | 2019 | 451 | 0.130 |
Why?
|
| Retrospective Studies | 8 | 2024 | 16043 | 0.130 |
Why?
|
| Neovascularization, Pathologic | 2 | 2006 | 240 | 0.120 |
Why?
|
| Enzyme Activation | 2 | 2014 | 617 | 0.120 |
Why?
|
| alpha-Crystallin B Chain | 1 | 2014 | 2 | 0.120 |
Why?
|
| Molecular Targeted Therapy | 1 | 2017 | 353 | 0.120 |
Why?
|
| Focal Adhesion Protein-Tyrosine Kinases | 1 | 2014 | 23 | 0.120 |
Why?
|
| Adenoviridae | 5 | 2019 | 608 | 0.120 |
Why?
|
| Gene Expression Regulation, Developmental | 1 | 2019 | 996 | 0.120 |
Why?
|
| CD8-Positive T-Lymphocytes | 2 | 2019 | 393 | 0.120 |
Why?
|
| Boronic Acids | 1 | 2014 | 48 | 0.120 |
Why?
|
| Calpain | 1 | 2014 | 41 | 0.120 |
Why?
|
| Chromatography, High Pressure Liquid | 1 | 2015 | 338 | 0.120 |
Why?
|
| Survival Rate | 2 | 2010 | 1999 | 0.120 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2016 | 810 | 0.110 |
Why?
|
| Pyrazines | 1 | 2014 | 73 | 0.110 |
Why?
|
| Hematopoiesis | 3 | 2023 | 217 | 0.110 |
Why?
|
| Interleukin-7 | 1 | 2014 | 44 | 0.110 |
Why?
|
| Sequence Homology, Amino Acid | 3 | 2006 | 657 | 0.110 |
Why?
|
| Adult Stem Cells | 1 | 2014 | 53 | 0.110 |
Why?
|
| Sequence Alignment | 3 | 2006 | 623 | 0.110 |
Why?
|
| Gene Expression Regulation, Enzymologic | 1 | 2014 | 256 | 0.110 |
Why?
|
| Feasibility Studies | 1 | 2016 | 755 | 0.110 |
Why?
|
| Interleukin-2 | 1 | 2014 | 224 | 0.110 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 2 | 2006 | 1290 | 0.110 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2015 | 510 | 0.110 |
Why?
|
| Blotting, Western | 1 | 2015 | 1100 | 0.100 |
Why?
|
| Down-Regulation | 1 | 2015 | 697 | 0.100 |
Why?
|
| Roseolovirus Infections | 1 | 2012 | 33 | 0.100 |
Why?
|
| Case-Control Studies | 2 | 2010 | 3233 | 0.100 |
Why?
|
| Disease Models, Animal | 3 | 2020 | 4285 | 0.100 |
Why?
|
| T-Lymphocytes, Regulatory | 1 | 2014 | 216 | 0.100 |
Why?
|
| Carcinoma, Hepatocellular | 1 | 2020 | 938 | 0.100 |
Why?
|
| Biomarkers | 3 | 2022 | 2943 | 0.090 |
Why?
|
| Disease Progression | 1 | 2017 | 2028 | 0.090 |
Why?
|
| Immunocompromised Host | 2 | 2012 | 295 | 0.090 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 2014 | 334 | 0.090 |
Why?
|
| Apoptosis | 3 | 2014 | 1782 | 0.090 |
Why?
|
| Oropharyngeal Neoplasms | 1 | 2013 | 154 | 0.090 |
Why?
|
| Liver Neoplasms | 1 | 2020 | 1311 | 0.090 |
Why?
|
| Cell Culture Techniques | 2 | 2019 | 287 | 0.090 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2012 | 472 | 0.080 |
Why?
|
| Uterine Cervical Neoplasms | 1 | 2013 | 237 | 0.080 |
Why?
|
| Dimerization | 2 | 2014 | 144 | 0.080 |
Why?
|
| Myocytes, Cardiac | 1 | 2014 | 618 | 0.080 |
Why?
|
| Child | 8 | 2024 | 24221 | 0.080 |
Why?
|
| Papillomavirus Infections | 1 | 2013 | 284 | 0.080 |
Why?
|
| Mice, Transgenic | 4 | 2020 | 2395 | 0.080 |
Why?
|
| United States | 2 | 2021 | 10649 | 0.080 |
Why?
|
| Gout | 1 | 2011 | 146 | 0.080 |
Why?
|
| Tissue Donors | 2 | 2021 | 496 | 0.070 |
Why?
|
| Lymphoma, AIDS-Related | 1 | 2007 | 37 | 0.070 |
Why?
|
| Spinal Cord Compression | 1 | 2007 | 30 | 0.070 |
Why?
|
| T-Cell Antigen Receptor Specificity | 2 | 2021 | 58 | 0.070 |
Why?
|
| Reproducibility of Results | 2 | 2022 | 2826 | 0.070 |
Why?
|
| Spinal Neoplasms | 1 | 2007 | 59 | 0.070 |
Why?
|
| Thrombospondins | 1 | 2006 | 13 | 0.070 |
Why?
|
| Molecular Sequence Data | 4 | 2006 | 3867 | 0.070 |
Why?
|
| Dendritic Cells | 1 | 2009 | 403 | 0.070 |
Why?
|
| Ischemia | 2 | 2006 | 343 | 0.070 |
Why?
|
| Tumor Microenvironment | 2 | 2022 | 533 | 0.070 |
Why?
|
| Burkitt Lymphoma | 1 | 2007 | 146 | 0.070 |
Why?
|
| Leishmania mexicana | 1 | 2006 | 5 | 0.070 |
Why?
|
| Coculture Techniques | 2 | 2019 | 233 | 0.060 |
Why?
|
| DNA Primers | 2 | 2006 | 660 | 0.060 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 2 | 2006 | 1012 | 0.060 |
Why?
|
| Leukocytes, Mononuclear | 2 | 2022 | 324 | 0.060 |
Why?
|
| Meningeal Neoplasms | 1 | 2007 | 183 | 0.060 |
Why?
|
| Amino Acid Sequence | 3 | 2006 | 2695 | 0.060 |
Why?
|
| Histidine | 1 | 2005 | 72 | 0.060 |
Why?
|
| Receptor, TIE-2 | 1 | 2005 | 13 | 0.060 |
Why?
|
| Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2005 | 66 | 0.060 |
Why?
|
| Cell Survival | 2 | 2019 | 808 | 0.060 |
Why?
|
| Telomerase | 1 | 2006 | 161 | 0.060 |
Why?
|
| Protein Structure, Tertiary | 3 | 2014 | 752 | 0.060 |
Why?
|
| RNA Splicing | 1 | 2005 | 224 | 0.060 |
Why?
|
| Acetates | 1 | 2024 | 71 | 0.060 |
Why?
|
| Heparin | 1 | 2005 | 227 | 0.060 |
Why?
|
| Calorimetry, Differential Scanning | 1 | 2003 | 6 | 0.060 |
Why?
|
| Cell Line | 2 | 2022 | 2771 | 0.050 |
Why?
|
| Circular Dichroism | 1 | 2003 | 86 | 0.050 |
Why?
|
| Solutions | 1 | 2003 | 65 | 0.050 |
Why?
|
| X-Ray Diffraction | 1 | 2003 | 95 | 0.050 |
Why?
|
| Mice, Inbred C57BL | 3 | 2006 | 4355 | 0.050 |
Why?
|
| Thermodynamics | 1 | 2003 | 144 | 0.050 |
Why?
|
| Restriction Mapping | 1 | 2003 | 188 | 0.050 |
Why?
|
| Regeneration | 1 | 2005 | 201 | 0.050 |
Why?
|
| Cell Count | 1 | 2003 | 250 | 0.050 |
Why?
|
| Neutropenia | 1 | 2024 | 202 | 0.050 |
Why?
|
| Endothelial Cells | 1 | 2006 | 528 | 0.050 |
Why?
|
| Protein Folding | 1 | 2003 | 218 | 0.050 |
Why?
|
| Antigen-Presenting Cells | 1 | 2003 | 117 | 0.050 |
Why?
|
| Incidence | 1 | 2010 | 3039 | 0.050 |
Why?
|
| Carmustine | 1 | 2022 | 26 | 0.050 |
Why?
|
| Thrombocytopenia | 1 | 2024 | 228 | 0.050 |
Why?
|
| Immunological Synapses | 1 | 2022 | 26 | 0.050 |
Why?
|
| Melphalan | 1 | 2022 | 49 | 0.050 |
Why?
|
| Cytarabine | 1 | 2022 | 98 | 0.050 |
Why?
|
| Benchmarking | 1 | 2003 | 132 | 0.050 |
Why?
|
| Cell Division | 1 | 2003 | 780 | 0.050 |
Why?
|
| Protein Conformation | 1 | 2003 | 833 | 0.050 |
Why?
|
| Rituximab | 1 | 2022 | 155 | 0.050 |
Why?
|
| Cell Lineage | 1 | 2003 | 340 | 0.050 |
Why?
|
| Hep G2 Cells | 1 | 2020 | 88 | 0.040 |
Why?
|
| Allografts | 1 | 2021 | 190 | 0.040 |
Why?
|
| Mice, Knockout | 3 | 2020 | 3722 | 0.040 |
Why?
|
| Demography | 1 | 2021 | 239 | 0.040 |
Why?
|
| Computer Simulation | 1 | 2003 | 630 | 0.040 |
Why?
|
| Protein Structure, Secondary | 2 | 2014 | 239 | 0.040 |
Why?
|
| Prognosis | 2 | 2021 | 4512 | 0.040 |
Why?
|
| Receptors, CCR7 | 1 | 2019 | 20 | 0.040 |
Why?
|
| Epstein-Barr Virus Infections | 1 | 2023 | 289 | 0.040 |
Why?
|
| Chronic Disease | 1 | 2024 | 1162 | 0.040 |
Why?
|
| Receptors, Odorant | 1 | 2019 | 36 | 0.040 |
Why?
|
| Recombinant Proteins | 1 | 2003 | 1386 | 0.040 |
Why?
|
| Epidermis | 1 | 2019 | 60 | 0.040 |
Why?
|
| Machine Learning | 1 | 2022 | 220 | 0.040 |
Why?
|
| Antigens, Viral | 2 | 2012 | 435 | 0.040 |
Why?
|
| Antigens, CD7 | 1 | 2018 | 11 | 0.040 |
Why?
|
| Base Sequence | 1 | 2003 | 3091 | 0.040 |
Why?
|
| Artificial Intelligence | 1 | 2022 | 239 | 0.040 |
Why?
|
| Cytoskeleton | 1 | 2019 | 178 | 0.040 |
Why?
|
| Patient Selection | 1 | 2022 | 683 | 0.040 |
Why?
|
| Killer Cells, Natural | 1 | 2020 | 320 | 0.040 |
Why?
|
| Extracellular Matrix | 1 | 2019 | 232 | 0.040 |
Why?
|
| Myeloid Cells | 1 | 2018 | 98 | 0.040 |
Why?
|
| Alleles | 1 | 2003 | 1603 | 0.040 |
Why?
|
| Lentivirus | 1 | 2018 | 83 | 0.040 |
Why?
|
| Sensitivity and Specificity | 1 | 2003 | 2011 | 0.040 |
Why?
|
| Microfilament Proteins | 1 | 2019 | 275 | 0.040 |
Why?
|
| Gene Editing | 1 | 2019 | 190 | 0.040 |
Why?
|
| Adenoviruses, Human | 1 | 2017 | 81 | 0.040 |
Why?
|
| BK Virus | 1 | 2017 | 59 | 0.030 |
Why?
|
| Models, Molecular | 2 | 2014 | 1070 | 0.030 |
Why?
|
| Plasmids | 1 | 2018 | 511 | 0.030 |
Why?
|
| Hemiarthroplasty | 1 | 2016 | 5 | 0.030 |
Why?
|
| Homeostasis | 2 | 2014 | 683 | 0.030 |
Why?
|
| Chemokine CXCL12 | 2 | 2006 | 33 | 0.030 |
Why?
|
| Chemokines, CXC | 2 | 2006 | 39 | 0.030 |
Why?
|
| Child, Preschool | 2 | 2024 | 13888 | 0.030 |
Why?
|
| Range of Motion, Articular | 1 | 2016 | 73 | 0.030 |
Why?
|
| Thrombopoiesis | 2 | 2006 | 12 | 0.030 |
Why?
|
| Cell Movement | 1 | 2019 | 831 | 0.030 |
Why?
|
| Time Factors | 2 | 2018 | 6218 | 0.030 |
Why?
|
| Cohort Studies | 1 | 2024 | 4699 | 0.030 |
Why?
|
| X-Linked Inhibitor of Apoptosis Protein | 1 | 2014 | 9 | 0.030 |
Why?
|
| Luciferases, Firefly | 1 | 2014 | 14 | 0.030 |
Why?
|
| Organic Chemicals | 1 | 2014 | 59 | 0.030 |
Why?
|
| Bortezomib | 1 | 2014 | 73 | 0.030 |
Why?
|
| Fluorescence Resonance Energy Transfer | 1 | 2014 | 63 | 0.030 |
Why?
|
| Survival Analysis | 1 | 2018 | 1473 | 0.030 |
Why?
|
| Receptors, Antigen | 1 | 2014 | 34 | 0.030 |
Why?
|
| Immunoblotting | 1 | 2014 | 312 | 0.030 |
Why?
|
| src-Family Kinases | 1 | 2014 | 90 | 0.030 |
Why?
|
| Stress, Mechanical | 1 | 2014 | 170 | 0.030 |
Why?
|
| Lymphocyte Count | 1 | 2014 | 115 | 0.030 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2018 | 714 | 0.030 |
Why?
|
| Gene Silencing | 1 | 2014 | 236 | 0.030 |
Why?
|
| Rats, Wistar | 1 | 2014 | 359 | 0.030 |
Why?
|
| Gene Knockdown Techniques | 1 | 2014 | 350 | 0.030 |
Why?
|
| Protein Engineering | 1 | 2013 | 73 | 0.030 |
Why?
|
| Liver | 1 | 2020 | 1734 | 0.030 |
Why?
|
| Microscopy, Fluorescence | 1 | 2014 | 330 | 0.030 |
Why?
|
| Green Fluorescent Proteins | 1 | 2014 | 394 | 0.030 |
Why?
|
| Reoperation | 1 | 2016 | 818 | 0.030 |
Why?
|
| Follow-Up Studies | 1 | 2022 | 5038 | 0.030 |
Why?
|
| Phenotype | 2 | 2018 | 4226 | 0.030 |
Why?
|
| Cross-Sectional Studies | 1 | 2021 | 3367 | 0.030 |
Why?
|
| Transduction, Genetic | 1 | 2013 | 290 | 0.030 |
Why?
|
| Immunodominant Epitopes | 1 | 2012 | 50 | 0.030 |
Why?
|
| Chromosome Mapping | 2 | 2006 | 1081 | 0.030 |
Why?
|
| Cytotoxicity, Immunologic | 1 | 2012 | 263 | 0.020 |
Why?
|
| Colchicine | 1 | 2011 | 43 | 0.020 |
Why?
|
| Disease-Free Survival | 1 | 2013 | 859 | 0.020 |
Why?
|
| Aorta | 1 | 2014 | 542 | 0.020 |
Why?
|
| Risk Factors | 2 | 2016 | 10009 | 0.020 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2013 | 1004 | 0.020 |
Why?
|
| Allopurinol | 1 | 2011 | 70 | 0.020 |
Why?
|
| Phosphorylation | 1 | 2014 | 1610 | 0.020 |
Why?
|
| Steroids | 1 | 2011 | 201 | 0.020 |
Why?
|
| Monocytes | 1 | 2012 | 345 | 0.020 |
Why?
|
| Forkhead Transcription Factors | 1 | 2012 | 367 | 0.020 |
Why?
|
| Myocardium | 1 | 2014 | 986 | 0.020 |
Why?
|
| Positron-Emission Tomography | 1 | 2011 | 289 | 0.020 |
Why?
|
| Gene Expression | 1 | 2013 | 1565 | 0.020 |
Why?
|
| Acute Disease | 1 | 2011 | 1093 | 0.020 |
Why?
|
| Paraparesis | 1 | 2007 | 11 | 0.020 |
Why?
|
| Lumbosacral Region | 1 | 2007 | 33 | 0.020 |
Why?
|
| Rats | 1 | 2014 | 3651 | 0.020 |
Why?
|
| Prednisolone | 1 | 2007 | 72 | 0.020 |
Why?
|
| Vincristine | 1 | 2007 | 196 | 0.020 |
Why?
|
| Thrombopoietin | 1 | 2006 | 30 | 0.020 |
Why?
|
| Thrombospondin 1 | 1 | 2006 | 22 | 0.020 |
Why?
|
| Fatal Outcome | 1 | 2007 | 355 | 0.020 |
Why?
|
| Hindlimb | 1 | 2006 | 75 | 0.020 |
Why?
|
| Stilbenes | 1 | 2006 | 36 | 0.020 |
Why?
|
| Megakaryocytes | 1 | 2006 | 39 | 0.020 |
Why?
|
| Doxorubicin | 1 | 2007 | 300 | 0.020 |
Why?
|
| Antiretroviral Therapy, Highly Active | 1 | 2007 | 266 | 0.020 |
Why?
|
| DNA, Protozoan | 1 | 2006 | 29 | 0.020 |
Why?
|
| Leishmania major | 1 | 2006 | 24 | 0.020 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-1 | 1 | 2006 | 43 | 0.020 |
Why?
|
| Receptors, CXCR4 | 1 | 2006 | 58 | 0.020 |
Why?
|
| Phosphorylcholine | 1 | 2005 | 26 | 0.020 |
Why?
|
| Heparitin Sulfate | 1 | 2005 | 20 | 0.020 |
Why?
|
| Angiopoietin-1 | 1 | 2005 | 7 | 0.020 |
Why?
|
| Aged, 80 and over | 1 | 2016 | 6371 | 0.020 |
Why?
|
| Chromosomes | 1 | 2006 | 199 | 0.020 |
Why?
|
| Texas | 1 | 2013 | 3560 | 0.020 |
Why?
|
| Fluorouracil | 1 | 2005 | 128 | 0.010 |
Why?
|
| Species Specificity | 1 | 2005 | 548 | 0.010 |
Why?
|
| Cellular Senescence | 1 | 2005 | 162 | 0.010 |
Why?
|
| Postoperative Complications | 1 | 2016 | 3011 | 0.010 |
Why?
|
| Nucleic Acid Hybridization | 1 | 2004 | 396 | 0.010 |
Why?
|
| Phylogeny | 1 | 2006 | 694 | 0.010 |
Why?
|
| Prospective Studies | 1 | 2014 | 6027 | 0.010 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2011 | 2055 | 0.010 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2005 | 413 | 0.010 |
Why?
|
| Signal Transduction | 2 | 2005 | 4493 | 0.010 |
Why?
|
| Binding Sites | 1 | 2005 | 1292 | 0.010 |
Why?
|
| Analysis of Variance | 1 | 2004 | 1008 | 0.010 |
Why?
|
| Evolution, Molecular | 1 | 2006 | 673 | 0.010 |
Why?
|
| Cell Cycle | 1 | 2004 | 614 | 0.010 |
Why?
|
| Peptides | 1 | 2005 | 794 | 0.010 |
Why?
|
| Models, Statistical | 1 | 2004 | 470 | 0.010 |
Why?
|
| Models, Genetic | 1 | 2004 | 760 | 0.010 |
Why?
|
| RNA | 1 | 2004 | 569 | 0.010 |
Why?
|
| Sequence Analysis, DNA | 1 | 2006 | 1751 | 0.010 |
Why?
|
| Computational Biology | 1 | 2004 | 804 | 0.010 |
Why?
|
| Models, Biological | 1 | 2004 | 1442 | 0.010 |
Why?
|
| RNA, Messenger | 1 | 2006 | 2809 | 0.010 |
Why?
|
| Transcription, Genetic | 1 | 2004 | 1702 | 0.010 |
Why?
|
| HIV Infections | 1 | 2007 | 1852 | 0.010 |
Why?
|
| Mutation | 1 | 2005 | 5769 | 0.010 |
Why?
|